A Phase II Trial Testing Olaparib in Metastatic or Advanced Urothelial Cancer Patients With DNA-Repair Defects

National Cancer Institute (NCI)
11 Feb, 2019 ,

This phase II trial studies how well olaparib works in treating patients with urothelial cancer with DNA-repair defects that has spread to other places in the body and usually cannot be cured or controlled with treatment. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.